About Protein tweety homolog 1
Protein tweety homolog 1 (TTYH1) is a protein
from Homo sapiens identified by UniProt accession
Q9H313, 450 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Protein tweety homolog 1 |
| UniProt accession | Q9H313 |
| Gene | TTYH1 |
| Organism | Homo sapiens |
| Length | 450 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (35)
Diseases linked to this target (Open Targets).
- idiopathic pulmonary fibrosis · score 0.23
- lymphocyte count · score 0.18
- glioblastoma multiforme · score 0.18
- breast adenocarcinoma · score 0.16
- head and neck squamous cell carcinoma · score 0.12
- self reported educational attainment · score 0.11
- drug use measurement · score 0.06
- cancer · score 0.04
- breast carcinoma · score 0.04
- medulloblastoma · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9H313-F1 | alphafold | PREDICTED | 89.65 | — |
Amino-acid sequence (450 residues)
MGAPPGYRPS AWVHLLHQLP RADFQLRPVP SVFAPQEQEY QQALLLVAAL AGLGLGLSLI FIAVYLIRFC CCRPPEPPGS KIPSPGGGCV TWSCIVALLA GCTGIGIGFY GNSETSDGVS QLSSALLHAN HTLSTIDHLV LETVERLGEA VRTELTTLEE VLEPRTELVA AARGARRQAE AAAQQLQGLA FWQGVPLSPL QVAENVSFVE EYRWLAYVLL LLLELLVCLF TLLGLAKQSK WLVIVMTVMS LLVLVLSWGS MGLEAATAVG LSDFCSNPDP YVLNLTQEET GLSSDILSYY LLCNRAVSNP FQQRLTLSQR ALANIHSQLL GLEREAVPQF PSAQKPLLSL EETLNVTEGN FHQLVALLHC RSLHKDYGAA LRGLCEDALE GLLFLLLFSL LSAGALATAL CSLPRAWALF PPSDDYDDTD DDDPFNPQES KRFVQWQSSI
Explore Protein tweety homolog 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets